Pharma Business - April 16, 2015
Recipharm Invests in Synthonics
Recipharm has made an equity investment in Synthonics Inc. and purchased $2.0 million of preferred stock in the company. An additional $2.0 million of preferred stock is expected to be purchased upon Synthonics’ achievement of certain milestones, which could occur during 2016, according to information from Recipharm. Synthonics and Recipharm also have entered into a […]